(MedPage Today) — CHICAGO — Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial showed.
After 16 cycles…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115874
Author :
Publish date : 2025-06-03 15:43:00
Copyright for syndicated content belongs to the linked Source.
